These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33557131)

  • 1. What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.
    Przybyl L; Wozna-Wysocka M; Kozlowska E; Fiszer A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of Huntington's disease and quest for therapeutic biomarkers.
    Kotrcova E; Jarkovska K; Valekova I; Zizkova M; Motlik J; Gadher SJ; Kovarova H
    Proteomics Clin Appl; 2015 Feb; 9(1-2):147-58. PubMed ID: 25290828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Glimpse of Molecular Biomarkers in Huntington's Disease.
    Martí-Martínez S; Valor LM
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients.
    Chang KH; Wu YR; Chen CM
    Orphanet J Rare Dis; 2017 Dec; 12(1):185. PubMed ID: 29258536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The updated development of blood-based biomarkers for Huntington's disease.
    Zhang S; Cheng Y; Shang H
    J Neurol; 2023 May; 270(5):2483-2503. PubMed ID: 36692635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.
    Silajdžić E; Björkqvist M
    J Huntingtons Dis; 2018; 7(2):109-135. PubMed ID: 29614689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
    Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
    Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease.
    Cesca F; Bregant E; Peterlin B; Zadel M; Dubsky de Wittenau G; Siciliano G; Ceravolo R; Petrozzi L; Pauletto G; Verriello L; Bergonzi P; Damante G; Barillari G; Lucci B; Curcio F; Lonigro IR
    PLoS One; 2015; 10(4):e0125259. PubMed ID: 25915065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biofluid Biomarkers in Huntington's Disease.
    Rodrigues FB; Byrne LM; Wild EJ
    Methods Mol Biol; 2018; 1780():329-396. PubMed ID: 29856027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A link between chromatin condensation mechanisms and Huntington's disease: connecting the dots.
    Lokhande S; Patra BN; Ray A
    Mol Biosyst; 2016 Nov; 12(12):3515-3529. PubMed ID: 27714015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.
    Fazio P; Paucar M; Svenningsson P; Varrone A
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):85. PubMed ID: 30291526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Roles of Exosomes in Huntington's Disease.
    Ananbeh H; Vodicka P; Kupcova Skalnikova H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer: From Wild-Type to Mutant Huntingtin.
    Thion MS; Humbert S
    J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntington's Disease.
    Ghavami A; Olsen M; Kwan M; Beltran J; Shea J; Ramboz S; Duan W; Lavery D; Howland D; Park LC
    J Huntingtons Dis; 2020; 9(1):13-31. PubMed ID: 32007959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's Disease: Relationship Between Phenotype and Genotype.
    Sun YM; Zhang YB; Wu ZY
    Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.